Screening, randomization, and follow-up of the study patients. The principal investigator was immediately notified when Candida spp. were cultured in blood. With at least one systemic inflammatory response syndrome (SIRS) symptom present in the 24 hours prior to blood culture withdrawal, and administration of systemic antifungal therapy < 72 hours, patients were deemed eligible for the ‘IFN-γ as an adjunctive treatment for candidemia’ pilot-study. In addition, 5 patients not meeting inclusion criteria but who were also treated with rIFN-γ as a therapy of last resort, were included in analysis.